Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

The Differential Diagnosis and Prognosis of Idiopathic and Atypical Parkinson Disease by Using Diffusion MRI

5. August 2021 aktualisiert von: Wang . Jiun-Jie, Chang Gung Memorial Hospital

The hypothesis is that the differential extent of microstructural damages in the affected brain regions can be specific to the disease of interest and could reflect the clinical severity. Therefore, we propose that the whole brain parcellation of diffusion MRI can be used to improve the diagnosis and prediction of clinical outcomes in Parkinson's Disease.

  1. A regression model between clinical severity and two-year clinical outcomes and diffusion properties from multiple parcellated regions will be developed.
  2. Blind validation will be performed.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Detaillierte Beschreibung

Parkinson's disease (PD) is a common progressive neurodegenerative disorder characterized by resting tremor, bradykinesia, restricted mobility, and postural instability. Early diagnosis of PD would be paramount for further treatment and prognosis. The most common neurodegenerative parkinsonian syndrome is known as Parkinson's disease (PD) or idiopathic Parkinson syndrome, if it occurs sporadically (not familial) and its lead clinical symptom is a movement disorder after brainstem-predominant α-synuclein deposition. To distinguish them from Parkinson's disease, other sporadic entities have been named atypical parkinsonian syndromes or atypical parkinsonism. The present review article describes current standards for the diagnosis and treatment of the most important disease entities in this latter group: dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD).

PD is diagnosed mainly by neurologists, based on clinical symptoms. However, there are no objective criteria available for their diagnosis. Although magnetic resonance imaging (MRI) is often employed in conjunction with clinical judgment, the images are mostly used to eliminate other diseases, rather than to confirm the diagnosis. Other imaging methods, such as Positron Emission Tomography or Computed Tomography, may help in the diagnosis of PD but have harmful effects on the human body. MRI image of patients with Parkinson's disease is usually normal. Previous studies have also indicated that brain-related areas, such as the atrophy of basal ganglia, are not observed until a period of disease progression. However, the shrinkage of brain tissue cannot be used as a criterion for the diagnosis of Parkinson's disease, because many other diseases are accompanied by atrophy of brain tissue as well. Furthermore, because human brain cells cannot regenerate, It is too late to diagnose or treat when a large number of nerve cells are apoptotic. Since we expect the function of the diseased cells to change first, therefore, if you can detect changes in the patient's brain microenvironment, it is possible to achieve early detection of Parkinson's disease. Magnetic resonance imaging can detect functional images and display functional changes, thus providing an opportunity to detect abnormalities and diagnose diseases early. One of the key technologies in the measurement of functional images is diffusion magnetic resonance imaging.

Diffusion MRI has been widely utilized to investigate the patterns of neural connectivity. Mean diffusivity (MD) and the directionality (fractional anisotropy (FA)) have been studied in epilepsy, multiple sclerosis, and noticeably in Parkinson's Disease. Owing to their paramount pathogenetic role in Parkinson's disease, the basal ganglia in general and the substantia nigra pars compacta, in particular, have been the subject of intense MRI investigation.

The plan uses standard anatomic labeling (AAL) to perform whole-brain diffusion MRI to obtain diffusion data for the whole brain parcellation. We will use statistical methods to identify the areas affected by each PD's subtype, we will also identify areas that are likely to be related to the severity of the disease, and then combine these areas for linear regression analysis. We anticipate that diffusion magnetic resonance imaging can be used as a differential diagnosis, as well as to define areas of high correlation with clinical severity, and to be used for accurate disease prediction and future development, and to provide physicians and patients with clinically important information.

The program uses diffusion magnetic resonance imaging to assess clinical status and prognosis for Parkinson's disease. Our research goal is

  1. Establish objective and clear imaging diagnostic criteria of diffusion MRI for idiopathic and atypical Parkinson's disease.
  2. Establish objective and clear clinical severity and the prognosis prediction mode of diffusion MRI for idiopathic and atypical Parkinson's disease.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

288

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Taoyuan, Taiwan, 333
        • ChangGung Memorial Hospital, Linkou

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

50 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

All subjects should meet the following criteria:

  1. Between 50-80 years old
  2. Right-handed
  3. Able to understand study requirements and give informed consent
  4. Agree to return for follow-up checks
  5. Able to suspend intake of medication for at least 12 hours

Beschreibung

Inclusion Criteria:

-

Exclusion Criteria:

  • Cardiac pacemaker or defibrillator implantation Intracranial metal device implantation
  • Other major systemic diseases, such as renal failure, heart failure, stroke, AMI/unstable angina, poorly controlled diabetes mellitus, poorly controlled hypertension
  • Alcohol or drug abuse
  • Moderate to severe dementia
  • Severe movement disorders
  • Imaging data is similar to a nuclear medical examination, exclusion criteria is any abnormality that may affect cognitive function as reflected in computer tomography or MRI records, such as hydrocephalus or encephalitis. Mild cortical atrophy is acceptable.
  • History of intracranial surgery including thalamotomy, pallidotomy, and/or deep brain stimulation
  • Major physical or neuropsychiatric disorders
  • Structural abnormalities that may cause dementia, such as cortical infarction, tumour, or subdural hematoma
  • Besides medication for Parkinson's Disease, taking other medication with substances that can pass through the blood-brain barrier
  • Besides medication for Parkinson's Disease, taking other medication for more than 10 years
  • Treatments or concurrent illnesses other than Alzheimer's Disease that could interfere with cognitive function
  • Meet the criteria for dementia (DSM-IV)
  • Head trauma with loss of consciousness greater than 10 minutes
  • Severe loss of sensation

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Atypical Parkinson's Disease patients
This group consists of patients includes 35 patients with Progressive Supranuclear Paralysis (PSP), 35 patients with Multiple System Atrophy (MSA), and 35 patients with Cortico-Basal Degeneration (CBD).
Idiopathic Parkinson's Disease patients
This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD)
Healthy volunteers

The 96 healthy volunteers should meet the following criteria:

  1. Between 50-80 years old
  2. Right-handed
  3. MMSE score greater than or equal to 26
  4. Able to understand study requirements and give informed consent

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Ein objektiver bildbasierter Beweis für die Diagnose, Differenzialdiagnose und Prognose der Parkinson-Krankheit
Zeitfenster: Ende des dritten Jahres

Für die diagnostische Leistungsfähigkeit der Diffusions-MRT werden gemessen:

  1. Regression zwischen kognitiver Leistung und Baseline-Diffusions-MRT mittels Pearson-Korrelation
  2. Lassen Sie eine Kreuzvalidierung weg
Ende des dritten Jahres

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
differential diagnosis
Zeitfenster: end of the second year
To differentiate patient of PD from PD + using diffusion MRI
end of the second year
prognosis
Zeitfenster: end of the third year
To predict the outcome of patient with PD using the diffusion MRI at baseline
end of the third year
prognosis
Zeitfenster: end of the third year
Methods for evaluation of worsening cognitive function in neurodegenerative disease
end of the third year
Imaging
Zeitfenster: end of the third year
High-quality diffusion MRI and image data restoration
end of the third year
Bildgebung
Zeitfenster: Ende des dritten Jahres
Hochwertige Diffusions-MRT-Bildgebungsstandards, Parzellierungsmethoden und Bildverarbeitungsprotokoll
Ende des dritten Jahres

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. August 2017

Primärer Abschluss (Tatsächlich)

1. August 2018

Studienabschluss (Tatsächlich)

31. Juli 2020

Studienanmeldedaten

Zuerst eingereicht

14. Juni 2020

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. Juli 2020

Zuerst gepostet (Tatsächlich)

15. Juli 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. August 2021

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

5. August 2021

Zuletzt verifiziert

1. August 2021

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Parkinson Krankheit

3
Abonnieren